Overview

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients <18 years old with a confirmed or suspected bacterial infection.

Phase:

Phase 1

Details

Lead Sponsor:

Melinta Therapeutics, Inc.
The Medicines Company

Treatments:

Oritavancin